COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
2020 ◽
Vol 4
(18)
◽
pp. 4278-4281
◽
Keyword(s):
Key Points COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.
Keyword(s):
2008 ◽
Vol 71
(6)
◽
pp. 831-841
◽
2008 ◽
Vol 71
(6)
◽
pp. 842-842
Keyword(s):
Keyword(s):
1999 ◽
Vol 16
◽
pp. S86-S88
◽
Keyword(s):